What’s the current market cap for Zealand Pharma A/S stock?

Zealand Pharma A/S (ZEAL) has a market cap of €2.7bn as of June 19, 2026.

What is the P/E ratio for Zealand Pharma A/S stock?

The price to earnings (P/E) ratio for Zealand Pharma A/S (ZEAL) stock is 3.11 as of June 19, 2026.

Does Zealand Pharma A/S stock pay dividends?

No, Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders as of June 19, 2026.

When is the next Zealand Pharma A/S dividend payment date?

Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders.

What is the beta indicator for Zealand Pharma A/S?

Zealand Pharma A/S (ZEAL) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Zealand Pharma A/S stock | €ZEAL Share Price

05:30

09:10

12:45

16:25

20:00

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. The company is headquartered in Copenhagen, Denmark, and operates in the pharmaceutical industry. Zealand Pharma's portfolio includes several marketed products and a robust pipeline addressing gastrointestinal, metabolic, and other specialty disease areas. Notably, their therapeutic offerings include dasiglucagon for severe hypoglycemia and other proprietary peptides. The company leverages its unique peptide platform to enhance drug discovery and development processes, aiming to deliver targeted treatments with potentially improved safety and efficacy profiles.

Ticker

€ZEAL

Sector

Health

Primary listing

XGAT

Employees

544

Headquarters

Søborg, Denmark

Website

www.zealandpharma.com

ZEAL Metrics

BasicAdvanced

€2.7bn

3.11

€11.96

0.55

Bulls say / Bears say

Initiation of a $200 million share buy-back program demonstrates management's confidence in Zealand's valuation and commitment to returning capital to shareholders.

Positive Phase III SYNCHRONIZE-1 results for survodutide, with an average 16.6% weight loss over 76 weeks, validate Zealand’s potential in the fast-growing obesity market.

Expected milestone payments of up to $700 million from Roche in 2026 bolster Zealand’s cash runway, reducing the need for dilutive financing to fund late-stage trials.

High operating loss in Q1 2026 of DKK 539 million highlights aggressive cash burn on R&D with no product revenue to offset expenses.

Mid-stage trial results for petrelintide fell short of investor expectations, triggering a >30% share plunge—the stock’s worst trading day on record on March 6, 2026, underscoring binary pipeline risk.

The company’s liquidity is heavily reliant on up to $700 million in partner-milestone payments from Roche in 2026, exposing its funding runway to external approval and development timelines.

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Bulls say / Bears say

Initiation of a $200 million share buy-back program demonstrates management's confidence in Zealand's valuation and commitment to returning capital to shareholders.

Positive Phase III SYNCHRONIZE-1 results for survodutide, with an average 16.6% weight loss over 76 weeks, validate Zealand’s potential in the fast-growing obesity market.

Expected milestone payments of up to $700 million from Roche in 2026 bolster Zealand’s cash runway, reducing the need for dilutive financing to fund late-stage trials.

High operating loss in Q1 2026 of DKK 539 million highlights aggressive cash burn on R&D with no product revenue to offset expenses.

The company’s liquidity is heavily reliant on up to $700 million in partner-milestone payments from Roche in 2026, exposing its funding runway to external approval and development timelines.

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

About Zealand Pharma A/S

Ticker

Primary listing

Employees

Headquarters

ZEAL Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €ZEAL

Lightyear

Legal

Work with us

Bulls say / Bears say

Zealand Pharma A/S/€ZEAL

About Zealand Pharma A/S

Ticker

Primary listing

Employees

Headquarters

ZEAL Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Zealand Pharma A/S stock?

What is the P/E ratio for Zealand Pharma A/S stock?

Does Zealand Pharma A/S stock pay dividends?

When is the next Zealand Pharma A/S dividend payment date?

What is the beta indicator for Zealand Pharma A/S?

Bulls say / Bears say